Methods for Treating Allergic Rhinitis and Eosinophilic Chronic Rhinosinusitis Through Mast Cell Tryptase Inhibition Identified by Single-Cell Transcriptomic Analysis of Human Nasal Polyp Tissue — USPTO Provisional Patent Specification

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification (Ritschel Research, filed 2026) disclosing methods and compositions for treating allergic rhinitis and eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP) through inhibition of mast cell tryptase (TPSAB1) in nasal mucosal mast cells. Lead compounds were identified by a computational pipeline applied to the human nasal polyp scRNA-seq dataset GSE156285. ScVI dimensionality reduction and Leiden clustering identified 12 cell populations from 1,635 high-quality cells; a mast cell / type 2 inflammation signature identified clusters 5, 3, and 7 as mast cell-enriched populations. Wilcoxon differential expression yielded 245 upregulated genes including TPSAB1, TPSB2, CPA3, MS4A2, HDC, and HPGDS. ChEMBL drug screening identified 674 NOVEL_ALL tryptase inhibitor candidates, all patent-clear for the nasal / allergic rhinitis / eCRSwNP indication. Lead compounds: CHEMBL46809 (pChEMBL 10.15), CHEMBL297220 (pChEMBL 9.40), CHEMBL310290 (pChEMBL 9.22), CHEMBL4460840 (CPA3, pChEMBL 9.41). TPSAB1 inhibition targets PAR-2-mediated neurogenic inflammation — a mechanism unaddressed by any approved therapy. Pipeline: github.com/glenritschel/crswn-scrna.

Fields of Study & Subjects

Mast cells and histamine Sinusitis and nasal conditions Allergic Rhinitis and Sensitization

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
22 March 2026
Language
EN